These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 26095234)

  • 1. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague.
    Nguyen D; Shaik JS; Tai G; Tiffany C; Perry C; Dumont E; Gardiner D; Barth A; Singh R; Hossain M
    Br J Clin Pharmacol; 2022 Feb; 88(2):416-428. PubMed ID: 34289143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
    Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):297-310. PubMed ID: 38782791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
    Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
    AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.
    Li T; Zhou S; Wang L; Zhao T; Wang J; Shao F
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):367-384. PubMed ID: 38554227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
    Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis.
    Hudachek SF; Gustafson DL
    J Pharm Sci; 2011 Mar; 100(3):1156-66. PubMed ID: 20803616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.
    Bradshaw-Pierce EL; Eckhardt SG; Gustafson DL
    Clin Cancer Res; 2007 May; 13(9):2768-76. PubMed ID: 17473210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.
    Janssen JM; Zwaan CM; Schellens JHM; Beijnen JH; Huitema ADR
    Eur J Cancer; 2017 Nov; 85():78-85. PubMed ID: 28892776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.
    Peigné S; Bouzom F; Brendel K; Gesson C; Fouliard S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):13-27. PubMed ID: 26563503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.
    Abduljalil K; Jamei M; Rostami-Hodjegan A; Johnson TN
    AAPS J; 2014 May; 16(3):568-76. PubMed ID: 24700271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.
    Calvier EAM; Nguyen TT; Johnson TN; Rostami-Hodjegan A; Tibboel D; Krekels EHJ; Knibbe CAJ
    Pharm Res; 2018 Sep; 35(11):209. PubMed ID: 30218393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population.
    Lim A; Sharma P; Stepanov O; Reddy VP
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.
    Zhou W; Johnson TN; Xu H; Cheung S; Bui KH; Li J; Al-Huniti N; Zhou D
    CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):475-83. PubMed ID: 27566992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
    Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
    Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of PBPK modeling across the pediatric age range using propofol as a case.
    Michelet R; Van Bocxlaer J; Allegaert K; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):765-785. PubMed ID: 30298439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
    Saeheng T; Na-Bangchang K; Karbwang J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.